Drawing for V-CHECK

USPTO serial 87660571

V-CHECK

Reviewed by CopyMark Law Group

Reg. 5897761Status 710
Filing date
Status date
Registration date
Oct 29, 2019
Examiner
HALMEN, KATHERINE E
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with V-CHECK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

M. Scott Alprin

M. Scott Alprin Alprin Law Offices, P.C.5 Pinehurst Circle, N.W.Washington, 20015JAPAN

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical agents for immune enhancement; drugs for human, namely, pharmaceutical preparations for reproductive medicine, women health, cirrhosis, hepatitis; contrast media for clinical diagnosis for medical use; contrast agent for clinical application, namely, contrast agent in the nature of contrast media for medical use for use in immunoassay, in vitro diagnostic kits and clinical medical reagents; bio-reagent for clinical applications, namely, immunoassay in the nature of medical diagnostic assays for testing of body fluids, in vitro diagnostic kit comprised of medical diagnostic assays for testing of body fluids, and clinical medical reagent; chemical agent for clinical applications, namely, immunoassay in the nature of medical diagnostic assays for testing of body fluids, in vitro diagnostic kit comprised of medical diagnostic assays for testing of body fluids, and clinical medical reagent; radiographic x-ray contrast agent; protease for clinical applications, namely, protease enzymes for medical purposes for use in reproductive medicine, women health, cirrhosis, and hepatitis; vaccine; chemical agents namely, immunoassay in the nature of medical diagnostic assays for testing of body fluids, in vitro diagnostic kit comprised of medical diagnostic assays for testing of body fluids, and clinical medical reagent; adjuvant for medical purposes for clinical applications; medicinal preparations for prevention and treatment of reproductive medical conditions, women's health conditions, cirrhosis, and hepatitis; pregnancy test kits for home use and clinical use; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection in the fields of reproductive medicine, women health, cirrhosis, hepatitis; chemical drugs for clinical applications, namely, pharmaceutical preparations for reproductive medicine, women health, cirrhosis, hepatitis; diagnostic kit comprised of medical diagnostic reagents and assays that test for the presence of reproductive medical conditions, women's health conditions, cirrhosis, hepatitis; diagnostic test for disease related biomarkers, namely, protein arrays for medical diagnosis purposes in the nature of alpha 1 antitrypsin and alpha 1 antitrypsin isoforms and the peptides derived from alpha 1 antitrypsin, diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, detecting reproductive diseases, women's health conditions, cirrhosis, hepatitis; clinical medical reagents for diagnostic test; test strip for clinical applications, namely, medical diagnostic test strips for use in the field of reproductive medicine, women's health, cirrhosis, hepatitis; sanitary padsSECTION 8 - CANCELLEDJun 3, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
May 15, 2026C8..CANCELLED SEC. 8 (6-YR)—
Oct 29, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jul 21, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 21, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 21, 2023EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Jul 21, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 21, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 21, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 21, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 10, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 10, 2023ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jul 10, 2023EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Jul 10, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 10, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 10, 2023CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 10, 2023COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 29, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 21, 2019SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Sep 20, 2019CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Sep 20, 2019SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Sep 19, 2019AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Aug 26, 2019IUAFUSE AMENDMENT FILED—
Aug 26, 2019EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 6, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 4, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 4, 2019EX1GSOU EXTENSION 1 GRANTED—
Apr 4, 2019EXT1SOU EXTENSION 1 FILED—
Apr 4, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 9, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 14, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 14, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 25, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 5, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 5, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Jul 5, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 5, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 5, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 19, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 19, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 19, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 16, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 16, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 6, 2018DOCKASSIGNED TO EXAMINER—
Nov 7, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Nov 4, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 30, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance